CONNECT WITH US:
Jul 28, 2020 12:00 JST
Theragen Bio Co Ltd
Theragen Bio analyzes Korea's largest COVID-19 patient and coronavirus genomic data
SEOUL, KOREA, Jul 28, 2020 - (ACN Newswire) - Theragen Bio is conducting joint research on developing a new coronavirus (COVID-19) genomic big data in collaboration with the Korea Research Institute of Chemical Technology (KRICT), Kyungpook National University Hospital, and the Daegu Metropolitan Government.
The study will analyze the full genome of each patient and the SARS-CoV-2 virus using samples from approximately 1,000 COVID-19 patients in Daegu and Gyeongsangbuk-do provence, the largest coronavirus genomic analysis to be conducted in Korea.
Through this study, Theragen hopes to identify the infection correlation between patient genome and the SARS-CoV-2 virus genome, and apply it to future vaccine development. Theragen identified the genetic correlation while establishing big data for SARS-CoV-2 mutations.
Based on its own Next Generation Sequencing (NGS), Theragen's ultra-sensitive Covid-19 RNA analysis system can decode over 30,000 full-legnth RNA sequences per virus. The SARS-CoV-2 virus mutates frequently, however the system can check RNA mutation, replication, and generation.
In addition, the evolution of the SARS-CoV-2 virus can be traced back to understand the transmission mechanisms between humans and predict clinical patterns, identify high-risk groups, improve the efficiency of PCR-based diagnosis, and secure evidence for prevention and prevention strategies.
Hwang Tae-soon, the CEO of Theragen Bio, explains, "This research is the first attempt to analyze whether there are differences in infection susceptibility depending on the genetic predisposition of infected patients as well as mutations and the evolution of the virus. It will be applicable to various infectious diseases in the future, as well as clinical prediction and vaccine development."
In April, Theragen Bio collaborated on research for a high-resolution genetic map of SARS-CoV-2, developed by Narry Kim, head of the RNA research group at the Institute for Basic Science (IBS), Hyeshik Chang, a professor at the Department of Biological Sciences, Seoul National University, in collaboration with Korea National Institute of Health (KNIH) within Korea Centers for Disease Control & Prevention (KCDC).
This study found the location of the coronavirus gene and RNA variations, to identify the transcriptome composition and the proliferation principles of the virus. In May, Theragen Bio traced the Seoul Itaewon cluster infections by sequencing the genomic materials and RNA transcriptomes and found that this SARS-CoV-2 variation originated in the U.S.
Theragen Bio, formerly the genome division of Theragen Etex (Kosdaq:066700), was spun off in March, 2020 to actively pursue customized pharmaceutical & new drug development and other projects featuring genomic technology. For further iniformation, please visit www.theragenbio.com.
Contact: Hyun Kim
Theragen Bio Co., Ltd.
Source: Theragen Bio Co Ltd
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Mitsubishi Corporation Releases Financial Results for the Three Months Ended June 2020
Aug 13, 2020 15:33 JST
NEC and PERSOL CAREER Start PoC of Recruitment Service for International IT Engineers using Blockchain Technology
Aug 13, 2020 09:57 JST
Hitachi and Bombardier Awarded Contract to Supply 23 Very High-speed Frecciarossa Trains to Trenitalia for Operation by ILSA on Routes in Spain
Aug 12, 2020 17:56 JST
Hitachi Rail to Acquire Railway Technology Firm Perpetuum to Accelerate UK Digitization Strategy
Aug 12, 2020 17:33 JST
SDK Revises Forecast of Consolidated Performance for Full-year 2020
Aug 12, 2020 16:00 JST
Showa Denko Announces 2020 2Q Consolidated Financial Results
Aug 12, 2020 16:00 JST
Banqsoft Acquires Concent to Expand and Broaden its Market Position
Aug 12, 2020 09:18 JST
Mitsubishi Corporation: Commercial Operations Commence at Cameron LNG
Aug 11, 2020 09:07 JST
TOYOTA GAZOO Racing Back on Track at SPA
Aug 07, 2020 18:04 JST
Leveraging EV/PHEV as Resources for Virtual Power Plants Commencement of Trial Operation of V2G Business Demonstration Facilities
Aug 07, 2020 09:03 JST
SDK to Record Operating/Non-operating Expenses for Acquisition of Hitachi Chemical's Shares, and Extraordinary Loss
Aug 06, 2020 16:00 JST
Mitsubishi Corporation: Trials of "KnowRoute", AI-Controlled On-Demand Bus Service to Commence in Shiojiri City, Nagano Prefecture
Aug 06, 2020 13:36 JST
Honda's Consolidated Financial Summary for the Fiscal Q1 Ended June 30, 2020 and Forecasts for the FY Ending March 31, 2021
Aug 05, 2020 18:45 JST
DENSO Establishes Pittsburgh Innovation Lab to Accelerate Automated Driving R&D
Aug 05, 2020 16:09 JST
Fujitsu Enhances VPS Series to Drive DX for Production Preparation Tasks
Aug 05, 2020 12:30 JST
Mitsubishi Corporation: R&D on Use of CO2 in Concrete
Aug 05, 2020 11:13 JST
MHPS Receives Contract for AQCS Equipment for a Chemical Plant in Poland
Aug 04, 2020 15:19 JST
MHI Machine Tool Develops "FR Series" of Machines to Manufacture Gears for Robots
Aug 04, 2020 12:10 JST
MHPS to Change Company Name to "Mitsubishi Power"
Jul 31, 2020 16:02 JST
DENSO Announces First Quarter Financial Results
Jul 31, 2020 14:11 JST
More Latest Release >>